期刊
NANOMEDICINE
卷 10, 期 21, 页码 3203-3212出版社
FUTURE MEDICINE LTD
DOI: 10.2217/nnm.15.155
关键词
active targeting; clinical studies; lung cancer therapy; nanomedicine; nanoparticle; tumor mouse model
资金
- Nanosystems Initiative Munich (NIM)
Lung cancer is by far the most common cause of cancer-related deaths in the world. Nanoparticle-based therapies enable targeted drug delivery for lung cancer treatment with increased therapeutic efficiency and reduced systemic toxicity. At the same time, nanomedicine has the potential for multimodal treatment of lung cancer that may involve 'all-in-one' targeting of several tumor-associated cell types in a timely and spatially controlled manner. Therapeutic approaches, however, are hampered by a translational gap between basic scientists, clinicians and pharma industry due to suboptimal animal models and difficulties in scale-up production of nanoagents. This calls for a disease-centered approach with interdisciplinary basic and clinical research teams with the support of pharma industries.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据